Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Issue Date
2010-07MeSH
Antineoplastic AgentsDrug Resistance, Neoplasm
Female
Fusion Proteins, bcr-abl
Humans
Incidental Findings
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Middle Aged
Piperazines
Protein Kinase Inhibitors
Pyrimidines
RNA, Messenger
RNA, Neoplasm
Remission Induction
Tumor Markers, Biological
Metadata
Show full item recordCitation
Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia. 2010, 34 (7):e176-7 Leuk. Res.Journal
Leukemia researchDOI
10.1016/j.leukres.2010.01.025PubMed ID
20153526Item Type
ArticleLanguage
enISSN
1873-5835ae974a485f413a2113503eed53cd6c53
10.1016/j.leukres.2010.01.025